Zoloft lawsuits from across the country are being filed against manufacturer Pfizer, citing infant birth defects that plaintiffs (victims) say were caused by maternal usage of Zoloft. Pfizer filed a request to consolidate 59 such lawsuits into a multidistrict litigation (MDL No. 2342), which are currently pending in Illinois, Mississippi, Missouri, New York, Ohio and Pennsylvania.
What Does the MDL Mean for Zoloft Victims?
For plaintiffs who have filed cases against Zoloft, consolidation will mean that witnesses, expert testimony and the discovery process during which attorneys outline the facts of the cases will be shared. This conserves the resources of the plaintiffs, as well as the court. An MDL differs from a class action, because participants in an MDL retain certain rights, including the advantage of individual award amounts. This means that two people with vastly different injuries are not held to receiving the same compensation from the defendant. An MDL also prevents inconsistent rulings. If the MDL does not resolve the cases, they will each be transferred back to the court in which they were originally filed.
What is the Next Step?
A panel will meet in San Diego on March 29 to hear oral arguments about Pfizer’s motion to consolidate and to determine which district court should be the site of the MDL proceedings.
Those who wish to file a claim against Pfizer for congenital defects that may have been caused by use of Zoloft during pregnancy should do so immediately. The time to file is limited by the law, so contact one of our attorneys now for a free consultation. We will listen to your story, tell you about your legal rights and help you make the decision that is best for you and your family.